DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.95

Change

-0.10 (-1.10)%

Market Cap

USD 0.17B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.06 (+0.06%)

USD 16.05B
VGS:AU Vanguard MSCI International Sh..

-0.08 (-0.06%)

USD 8.59B
IVV:AU iShares Core S&P 500 AUD

+0.01 (+0.02%)

USD 8.26B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.17 (-0.31%)

USD 6.31B
IOZ:AU Ishares Core S&P/Asx 200

N/A

USD 5.96B
STW:AU SPDR® S&P/ASX 200 Fund

-0.01 (-0.01%)

USD 5.61B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.04 (+0.10%)

USD 4.86B
NDQ:AU Betashares Nasdaq 100

-0.02 (-0.05%)

USD 4.83B
A200:AU BetaShares Australia 200

+0.01 (+0.01%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+0.35 (+0.09%)

USD 4.70B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.01% 77% C+ 74% C
Dividend Return 3.15% 61% D- 51% F
Total Return 16.16% 80% B- 75% C
Trailing 12 Months  
Capital Gain 13.87% 65% D 72% C
Dividend Return 3.18% 45% F 36% F
Total Return 17.04% 63% D 71% C-
Trailing 5 Years  
Capital Gain 49.92% 87% B+ 78% C+
Dividend Return 10.78% 46% F 34% F
Total Return 60.70% 84% B 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 6.94% 77% C+ 58% F
Dividend Return 8.47% 74% C 57% F
Total Return 1.53% 50% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 8.36% 67% D+ 93% A
Risk Adjusted Return 101.28% 97% N/A 98% N/A
Market Capitalization 0.17B 34% F 66% D+

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.